The Importance of Testosterone Control in Prostate Cancer Bertrand Tombal  European Urology Supplements  Volume 6, Issue 15, Pages 834-839 (September 2007) DOI: 10.1016/j.eursup.2007.06.002 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Approximately 1–12.5% of the patients on conventional LHRH agonists do not achieve testosterone castration levels ≤50ng/dl. Deep orange indicate new data presented at the European Association of Urology 2007 meeting. European Urology Supplements 2007 6, 834-839DOI: (10.1016/j.eursup.2007.06.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 About 13–40% of the patients on conventional LHRH agonists do not reach testosterone castration levels ≤20ng/dl. Deep orange indicate new data presented at the European Association of Urology 2007 meeting. European Urology Supplements 2007 6, 834-839DOI: (10.1016/j.eursup.2007.06.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Approximately 10% of the patients on conventional LHRH agonists show injection-related testosterone escapes (miniflares), whereas 2–24% encounter breakthrough testosterone escapes. Deep orange indicate new data presented at the European Association of Urology 2007 meeting. European Urology Supplements 2007 6, 834-839DOI: (10.1016/j.eursup.2007.06.002) Copyright © 2007 European Association of Urology Terms and Conditions